Newly Discovered Anticancer Drug Approved by FDA

DRUG INDICATION MODE OF ACTION

Rucaparib (Rubraca) For treatment of patients with Rucaparib inhibits "the
deleterious BRCA mutation contraction of isolated
(germline and/or somatic)– vascular smooth muscle,
associated advanced ovarian including that from the
cancer who have been treated tumours of cancer patients. It
with two or more also reduces the migration of
chemotherapies. some cancer and normal cells
in culture
Avelumab (Bavencio) For the treatment of patient’s Binds to the programmed
≥ 12 years of age with death ligand 1 (PD-L1),
metastatic Merkel cell inhibits binding to its receptor
carcinoma. Avelumab is a programmed cell death 1(PD-
PD-L1 blocking human 1)
immunoglobulin G1λ
monoclonal antibody. This is
the first FDA-approved
product to treat this type of
cancer.
Niraparib (Zejula) Maintenance treatment for Inhibitor of the enzymes
adult patients with recurrent PARP1 and PARP2
epithelial ovarian, fallopian
tube, or primary peritoneal
cancer who are in complete or
partial response to platinum-
based chemotherapy.
Ribociclib (Kisqali) In combination with an Inhibitor of cyclin D1/ CDK4
aromatase inhibitor as initial and CDK6
endocrinebased therapy for
the treatment of
postmenopausal women with
HRpositive, HER2-negative
advanced or metastatic breast
cancer.
Brigatinib (Alunbrig For treatment of patients with Inhibitor of ALK and mutated
metastatic anaplastic EGFR
lymphoma kinase– positive
NSCLC who experienced
disease progression on or
who are intolerant to
crizotinib
Midostaurin (Rydapt) For treatment of adult Multi-targeted protein kinase
patients with newly inhibitor
diagnosed AML who are
FLT3 mutation–positive, as
 detected by an FDA-approved
test, in combination with
standard cytarabine and
daunorubicin induction and
cytarabine consolidation.
Durvalumab (Imfinzi) For treatment of patients with Blocks the interaction of
locally advanced or programmed cell death ligand
metastatic urothelial 1 (PDL1) with the PD-1 and
carcinoma who experience CD80 (B7.1
disease progression during or
after platinumcontaining
chemotherapy or who
experience disease
progression within 12 months
of neoadjuvant or adjuvant
treatment with
platinumcontaining
chemotherapy.
Rituximab and hyaluronidase For adult patients with Three major independent
human (Rituxan Hycela) follicular lymphoma, diffuse mechanisms are 1. Antibody
large B-cell lymphoma, and dependent cellular
chronic lymphocytic cytotoxicity 2. Complement
leukemia. mediated cytotoxicity 3.
Apoptosis, subst panel
illustrates a schematic view
of CD20 structure and
rituximab
Neratinib (Nerlynx) For extended adjuvant Dual inhibitor of the human
treatment of adult patients epidermal growth factor
with early-stage HER2- receptor 2 (Her2) and
overexpressed/amplified epidermal growth factor
breast cancer, to follow receptor (EGFR) kinases
adjuvant trastuzumab-based
therapy.
Daunorubicin and cytarabine For treatment of adults with Blocking the function of
(Vyxeos) newly diagnosed therapy- topoisomerase II
related AML or AML with
myelodysplasia-related
changes, two types of AML
that have a poor prognosis.
Enasidenib (Idhifa) For treatment of adult Inhibitor of IDH2
patients with relapsed or
refractory AML with an
isocitrate dehydrogenase-2
mutation as detected by an
FDA-approved test.
Inotuzumab ozogamicin For treatment of adults with Binds to CD22 receptor
(Besponsa) relapsed or refractory B-cell
precursor ALL.
Tisagenlecleucel (Kymriah) For treatment of patients ≤ 25 Treat B cell acute
years of age with B-cell lymphoblastic leukemia
precursor ALL that is
refractory or in second or
later relapse.
Abemaciclib (Verzenio) In combination with CDK inhibitor selective for
fulvestrant for women with CDK4 and CDK6
HR-positive, HER2- negative
advanced or metastatic breast
cancer with disease
progression after endocrine
therapy.
Bevacizumabawwb (Mvasi) Approved as a biosimilar to Blocks angiogenesis by
bevacizumab (Avastin), inhibiting vascular
bevacizumabawwb is the first endothelial growth factor A
biosimilar approved in the (VEGF-A)
United States for the
treatment of cancer.
Copanlisib (Aliqopa) For treatment of adult Inhibitor of
patients with relapsed phosphatidylinositol-3-
follicular lymphoma who kinase (PI3K)
have received at least two
prior systemic therapies.
Gemtuzumab ozogamicin Newly diagnosed CD33- Targets the membrane
(Mylotarg) positive AML in adults and antigen CD33
for treatment of relapsed or
refractory CD33-positive
AML in adults and pediatric
patient’s ≥ 2 years of age.
May be used in combination
with daunorubicin and
cytarabine for adults with
newly diagnosed AML or as a
stand-alone treatment of
certain adult and pediatric
patients.
Axicabtagene ciloleucel For treatment of adult An anti-CD19 chimeric
(Yescarta) patients with relapsed or antigen receptor (CAR T) cell
refractory large B-cell
lymphoma after two or more
lines of systemic therapy.